74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
EssilorLuxottica SA
Closed
Sector Healthcare
289.9 -0.96
Overview
Share price change
24h
Min
289.8
Max
293.9
Income | 1.4B |
|---|---|
Sales | 13B |
P/E Sector Avg | 57.29 73.394 |
EPS | 2.976 |
Dividend yield | 1.34 |
Profit margin | 10.271 |
Employees | 200,000 |
EBITDA | 3B |
Recommendations | Buy |
|---|---|
12 Months Forecast | -1.2 downside |
Dividend yield Sector Avg | 1.34% 3.09% |
|---|---|
Next Earnings | 17 Apr 2025 |
Market Cap | 13B 134B |
|---|---|
Previous open | 290.86 |
Previous close | 289.9 |
News Sentiment
By Acuity
32%
68%
95 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bullish Evidence
EssilorLuxottica SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
EssilorLuxottica SA Forecast
Price Target
By TipRanks
-1.2% downside
12 Months Forecast
Average 289 EUR -1.2%
High 335 EUR
Low 250 EUR
Based on 10 Wall Street analysts offering 12 month price targets forEssilorLuxottica SA - Dist in the last 3 months.
Sentiment
By Acuity
95 / 393 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About EssilorLuxottica SA
EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
